Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-1206 in Adults With Solid Tumors
NCT07703878Phase 1Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of GS-1206 in solid tumor (2 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing any Dose-limiting Toxicities at 21 days, Percentage of Participants Experiencing Treatment-Emergent Adverse Events and Serious Adverse Events at 3 years and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
GS-1206
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07703878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703878.